Details of the Drug

General Information of Drug (ID: DM53SRA)

• Drug Name: Prochlorperazine
• Synonyms: CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP

Indication

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[1]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 373.9
  Logarithm of the Partition Coefficient (xlogp); 4.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 h [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 12.5% [2]
  Clearance: The renal clearance of drug is 23.6 mL/h [4]
  Elimination: 0.1% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 9 - 8 hours [4]
  Metabolism: The drug is metabolized via the hepatic [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.828 micromolar/kg/day [6]
  Vd: The volume of distribution (Vd) of drug is 1401 L [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.1 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Metabolic disorder	Not Available	UGT1A1	OTH1C8OJ	[8]
Metabolic disorder	Not Available	G6PC	OTJ6FM9F	[8]

• Chemical Identifiers:
  Formula: C20H24ClN3S
  IUPAC Name: 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
  Canonical SMILES: CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
  InChI: InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
  InChIKey: WIKYUJGCLQQFNW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4917
  ChEBI ID: CHEBI:8435
  CAS Number: 58-38-8
  DrugBank ID: DB00433
  TTD ID: D0B2UZ
  VARIDT ID: DR00592
  INTEDE ID: DR1345
  ACDINA ID: D00559
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	OTJ6FM9F	G6PC1_HUMAN	Drug Response	[8]
Transcription factor EB (TFEB)	OTJUJJQY	TFEB_HUMAN	Protein Interaction/Cellular Processes	[11]
UDP-glucuronosyltransferase 1A1	OTH1C8OJ	UD11_HUMAN	Drug Response	[8]

Molecular Expression Atlas of This Drug

• The Studied Disease: Nausea
• ICD Disease Classification: MD90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prochlorperazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Droperidol.	Nausea/vomiting [MD90]	[12]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[13]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Promethazine.	Nausea/vomiting [MD90]	[13]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Cyclizine.	Nausea/vomiting [MD90]	[13]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Prochlorperazine and Metoclopramide.	Nausea/vomiting [MD90]	[14]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Dolasetron.	Nausea/vomiting [MD90]	[12]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ondansetron.	Nausea/vomiting [MD90]	[12]

Coadministration of a Drug Treating the Disease Different from Prochlorperazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[15]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[12]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[12]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[12]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Arn-509.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Oliceridine.	Acute pain [MG31]	[12]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Memantine.	Alzheimer disease [8A20]	[13]
Galantamine	DMEO794	Moderate	Antagonize the effect of Prochlorperazine when combined with Galantamine.	Alzheimer disease [8A20]	[19]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Prochlorperazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[19]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Prochlorperazine when combined with Donepezil.	Alzheimer disease [8A20]	[19]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Prochlorperazine and Metronidazole.	Amoebiasis [1A36]	[20]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Trimethaphan.	Aneurysm/dissection [BD50]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ivabradine.	Angina pectoris [BA40]	[16]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Bepridil.	Angina pectoris [BA40]	[12]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Dronedarone.	Angina pectoris [BA40]	[12]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Amyl nitrite.	Angina pectoris [BA40]	[22]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Nifedipine.	Angina pectoris [BA40]	[22]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[23]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[13]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Cilostazol.	Arterial occlusive disease [BD40]	[12]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Voriconazole.	Aspergillosis [1F20]	[12]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Levalbuterol.	Asthma [CA23]	[24]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Terbutaline.	Asthma [CA23]	[25]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Pirbuterol.	Asthma [CA23]	[25]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Salbutamol.	Asthma [CA23]	[24]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Formoterol.	Asthma [CA23]	[25]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Prochlorperazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[26]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Prochlorperazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[27]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[12]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[12]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[12]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Linezolid.	Bacterial infection [1A00-1C4Z]	[29]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[12]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[12]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Retigabine.	Behcet disease [4A62]	[12]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Cariprazine.	Bipolar disorder [6A60]	[13]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Prochlorperazine and Loperamide.	Bowel habit change [ME05]	[30]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Eribulin.	Breast cancer [2C60-2C6Y]	[12]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[12]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[12]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Toremifene.	Breast cancer [2C60-2C6Y]	[12]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sotalol.	Cardiac arrhythmia [BC9Z]	[12]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Prochlorperazine when combined with Acetylcholine.	Cataract [9B10]	[31]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[32]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[32]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[32]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Isoproterenol.	Conduction disorder [BC63]	[24]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Olopatadine.	Conjunctiva disorder [9A60]	[33]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Propofol.	Corneal disease [9A76-9A78]	[34]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sevoflurane.	Corneal disease [9A76-9A78]	[12]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Probucol.	Coronary atherosclerosis [BA80]	[12]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Clofazimine.	Crohn disease [DD70]	[35]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Mifepristone.	Cushing syndrome [5A70]	[12]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Pasireotide.	Cushing syndrome [5A70]	[12]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Cyclandelate.	Dementia [6D80-6D8Z]	[22]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sertraline.	Depression [6A70-6A7Z]	[12]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[13]
Imipramine	DM2NUH3	Moderate	Increased plasma concentrations of Prochlorperazine and Imipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[27]
Fluoxetine	DM3PD2C	Moderate	Additive antidopaminergic effects by the combination of Prochlorperazine and Fluoxetine.	Depression [6A70-6A7Z]	[36]
Nortriptyline	DM4KDYJ	Moderate	Increased plasma concentrations of Prochlorperazine and Nortriptyline due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[27]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Prochlorperazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Selegiline	DM6034S	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Selegiline.	Depression [6A70-6A7Z]	[29]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Prochlorperazine caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[38]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Tranylcypromine.	Depression [6A70-6A7Z]	[29]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and OPC-34712.	Depression [6A70-6A7Z]	[13]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Phenelzine.	Depression [6A70-6A7Z]	[29]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Prochlorperazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[27]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Trazodone.	Depression [6A70-6A7Z]	[39]
Amoxapine	DMKITQE	Moderate	Increased plasma concentrations of Prochlorperazine and Amoxapine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[27]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Prochlorperazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[40]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Maprotiline.	Depression [6A70-6A7Z]	[13]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Esketamine.	Depression [6A70-6A7Z]	[20]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[22]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Mepenzolate.	Digestive system disease [DE2Z]	[13]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Oxybutynine.	Discovery agent [N.A.]	[13]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Prochlorperazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[41]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Meclizine.	Dizziness and giddiness [MB48]	[13]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Prochlorperazine and Deutetrabenazine.	Dystonic disorder [8A02]	[42]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ingrezza.	Dystonic disorder [8A02]	[43]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Prochlorperazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[44]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Prochlorperazine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Guanabenz.	Essential hypertension [BA00]	[22]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Ethacrynic acid.	Essential hypertension [BA00]	[21]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bendroflumethiazide.	Essential hypertension [BA00]	[20]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Phenoxybenzamine.	Essential hypertension [BA00]	[22]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Nicardipine.	Essential hypertension [BA00]	[22]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Mecamylamine.	Essential hypertension [BA00]	[22]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Benzthiazide.	Essential hypertension [BA00]	[20]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Nadolol.	Essential hypertension [BA00]	[22]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Solifenacin.	Functional bladder disorder [GC50]	[12]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Prochlorperazine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[46]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Tolterodine.	Functional bladder disorder [GC50]	[13]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Prochlorperazine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[47]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Pentamidine.	Fungal infection [1F29-1F2F]	[12]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Prochlorperazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[48]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ketoconazole.	Fungal infection [1F29-1F2F]	[12]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Phentolamine.	Gangrene [MC85]	[22]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[12]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[12]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Prochlorperazine when combined with Isoflurophate.	Glaucoma [9C61]	[31]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Carteolol.	Glaucoma [9C61]	[22]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Brimonidine.	Glaucoma [9C61]	[49]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Prochlorperazine when combined with Pilocarpine.	Glaucoma [9C61]	[31]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Prazosin.	Heart failure [BD10-BD1Z]	[22]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Eplerenone.	Heart failure [BD10-BD1Z]	[22]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Carvedilol.	Heart failure [BD10-BD1Z]	[22]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[20]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Furosemide.	Heart failure [BD10-BD1Z]	[20]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Amiloride.	Heart failure [BD10-BD1Z]	[22]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bumetanide.	Heart failure [BD10-BD1Z]	[20]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[20]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Procarbazine.	Hodgkin lymphoma [2B30]	[29]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Prochlorperazine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[22]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Prochlorperazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[20]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Eprosartan.	Hypertension [BA00-BA04]	[22]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Acebutolol.	Hypertension [BA00-BA04]	[22]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Moexipril.	Hypertension [BA00-BA04]	[22]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Bisoprolol.	Hypertension [BA00-BA04]	[22]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Captopril.	Hypertension [BA00-BA04]	[22]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Penbutolol.	Hypertension [BA00-BA04]	[22]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Trandolapril.	Hypertension [BA00-BA04]	[22]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Methyldopa.	Hypertension [BA00-BA04]	[22]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Clonidine.	Hypertension [BA00-BA04]	[22]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Losartan.	Hypertension [BA00-BA04]	[22]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Nebivolol.	Hypertension [BA00-BA04]	[22]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Levamlodipine.	Hypertension [BA00-BA04]	[22]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Fosinopril.	Hypertension [BA00-BA04]	[22]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Doxazosin.	Hypertension [BA00-BA04]	[22]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Verapamil.	Hypertension [BA00-BA04]	[22]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and TAK-491.	Hypertension [BA00-BA04]	[22]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Pindolol.	Hypertension [BA00-BA04]	[22]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Fenoldopam.	Hypertension [BA00-BA04]	[22]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indapamide.	Hypertension [BA00-BA04]	[20]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Benazepril.	Hypertension [BA00-BA04]	[22]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Trichlormethiazide.	Hypertension [BA00-BA04]	[22]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Labetalol.	Hypertension [BA00-BA04]	[22]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Diazoxide.	Hypertension [BA00-BA04]	[22]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Enalapril.	Hypertension [BA00-BA04]	[22]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Perindopril.	Hypertension [BA00-BA04]	[22]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Felodipine.	Hypertension [BA00-BA04]	[22]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Quinapril.	Hypertension [BA00-BA04]	[22]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Deserpidine.	Hypertension [BA00-BA04]	[22]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Telmisartan.	Hypertension [BA00-BA04]	[22]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Irbesartan.	Hypertension [BA00-BA04]	[22]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Hydralazine.	Hypertension [BA00-BA04]	[22]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Lisinopril.	Hypertension [BA00-BA04]	[22]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[20]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[22]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[13]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Amantadine.	Influenza [1E30-1E32]	[54]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Propiomazine.	Insomnia [7A00-7A0Z]	[13]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and ITI-007.	Insomnia [7A00-7A0Z]	[13]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[12]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[12]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Clidinium.	Irritable bowel syndrome [DD91]	[13]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Prochlorperazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[19]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Prochlorperazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[16]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Crizotinib.	Lung cancer [2C25]	[55]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Porfimer Sodium.	Lung cancer [2C25]	[56]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ceritinib.	Lung cancer [2C25]	[12]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Osimertinib.	Lung cancer [2C25]	[57]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Lumefantrine.	Malaria [1F40-1F45]	[20]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Halofantrine.	Malaria [1F40-1F45]	[58]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Chloroquine.	Malaria [1F40-1F45]	[59]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[59]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Quinine.	Malaria [1F40-1F45]	[12]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Primaquine.	Malaria [1F40-1F45]	[12]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[60]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Vemurafenib.	Melanoma [2C30]	[12]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and LGX818.	Melanoma [2C30]	[61]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[62]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Propranolol.	Migraine [8A80]	[22]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Lasmiditan.	Migraine [8A80]	[63]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Flibanserin.	Mood disorder [6A60-6E23]	[64]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Panobinostat.	Multiple myeloma [2A83]	[65]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Thalidomide.	Multiple myeloma [2A83]	[66]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Fingolimod.	Multiple sclerosis [8A40]	[12]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ozanimod.	Multiple sclerosis [8A40]	[67]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Methoxsalen.	Mycosis fungoides [2B01]	[20]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Romidepsin.	Mycosis fungoides [2B01]	[12]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[12]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Prochlorperazine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[68]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Prochlorperazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[26]
Bupropion	DM5PCS7	Major	Decreased metabolism of Prochlorperazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[12]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Entrectinib.	Non-small cell lung cancer [2C25]	[20]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Prochlorperazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[26]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Prochlorperazine when combined with Amfepramone.	Obesity [5B80-5B81]	[26]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Prochlorperazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[69]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Prochlorperazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[26]
Mazindol	DMZ36RN	Moderate	Antagonize the effect of Prochlorperazine when combined with Mazindol.	Obesity [5B80-5B81]	[26]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Metolazone.	Oedema [MG29]	[20]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polythiazide.	Oedema [MG29]	[20]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Lofexidine.	Opioid use disorder [6C43]	[12]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Apraclonidine.	Optic nerve disorder [9C40]	[49]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Rucaparib.	Ovarian cancer [2C73]	[12]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Prochlorperazine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[70]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Flavoxate.	Pain [MG30-MG3Z]	[13]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Prochlorperazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[71]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Prochlorperazine and Buprenorphine.	Pain [MG30-MG3Z]	[72]
Meperidine	DMX4GND	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Meperidine.	Pain [MG30-MG3Z]	[73]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Triclabendazole.	Parasitic worm infestation [1F90]	[12]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Prochlorperazine when combined with Pergolide.	Parkinsonism [8A00]	[74]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Prochlorperazine when combined with Opicapone.	Parkinsonism [8A00]	[74]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Rasagiline.	Parkinsonism [8A00]	[29]
Biperiden	DME78OA	Moderate	Antagonize the effect of Prochlorperazine when combined with Biperiden.	Parkinsonism [8A00]	[75]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Prochlorperazine when combined with Entacapone.	Parkinsonism [8A00]	[74]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Prochlorperazine when combined with Levodopa.	Parkinsonism [8A00]	[74]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimavanserin.	Parkinsonism [8A00]	[76]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Prochlorperazine when combined with Bromocriptine.	Parkinsonism [8A00]	[74]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Orphenadrine.	Parkinsonism [8A00]	[13]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Methylscopolamine.	Peptic ulcer [DA61]	[13]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Famotidine.	Peptic ulcer [DA61]	[20]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[77]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Ritodrine.	Preterm labour/delivery [JB00]	[25]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Prochlorperazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilutamide.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Enzalutamide.	Prostate cancer [2C82]	[16]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Flutamide.	Prostate cancer [2C82]	[16]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Relugolix.	Prostate cancer [2C82]	[16]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Bicalutamide.	Prostate cancer [2C82]	[16]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Terazosin.	Prostate hyperplasia [GA90]	[22]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Tamsulosin.	Prostate hyperplasia [GA90]	[22]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Silodosin.	Prostate hyperplasia [GA90]	[22]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Verteporfin.	Psoriasis [EA90]	[16]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[13]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[13]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Tolazoline.	Pulmonary hypertension [BB01]	[22]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[79]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Prochlorperazine when combined with Neupro.	Restless legs syndrome [7A80]	[74]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Prochlorperazine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[80]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[13]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Quetiapine.	Schizophrenia [6A20]	[12]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Mesoridazine.	Schizophrenia [6A20]	[12]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Thioridazine.	Schizophrenia [6A20]	[81]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Aripiprazole.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Iloperidone.	Schizophrenia [6A20]	[12]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Paliperidone.	Schizophrenia [6A20]	[12]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Haloperidol.	Schizophrenia [6A20]	[12]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Perphenazine.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Molindone.	Schizophrenia [6A20]	[13]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpromazine.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Thiothixene.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Trifluoperazine.	Schizophrenia [6A20]	[13]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Risperidone.	Schizophrenia [6A20]	[13]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Amisulpride.	Schizophrenia [6A20]	[82]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Asenapine.	Schizophrenia [6A20]	[12]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimozide.	Schizophrenia [6A20]	[16]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[12]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[12]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[12]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Pitolisant.	Somnolence [MG42]	[12]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[12]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[12]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Lenvatinib.	Thyroid cancer [2D10]	[12]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Cabozantinib.	Thyroid cancer [2D10]	[16]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Prochlorperazine and Papaverine.	Tonus and reflex abnormality [MB47]	[22]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Prochlorperazine and Tizanidine.	Tonus and reflex abnormality [MB47]	[83]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Tacrolimus.	Transplant rejection [NE84]	[12]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Atropine.	Unspecific substance harmful effect [NE6Z]	[13]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[12]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[13]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[13]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[13]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[13]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Prochlorperazine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[13]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[12]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[12]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Prochlorperazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[12]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Prochlorperazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[12]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Aluminum lake	E00504	9989226	Other agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Prochlorperazine 10 mg tablet	10 mg	Oral Tablet	Oral
Prochlorperazine 5 mg tablet	5 mg	Oral Tablet	Oral
Prochlorperazine Maleate 5mg tablet	5mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7279).
• [2] Prochlorperazine Prescribing Information - AA Pharma
• [3] BDDCS applied to over 900 drugs
• [4] Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84.
• [5] Prochlorperazine - National Library of Medicine HSDB Database
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Taylor WB, Bateman DN: Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987 Feb;23(2):137-42. doi: 10.1111/j.1365-2125.1987.tb03021.x.
• [8] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [9] In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102.
• [10] Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
• [11] Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
• [12] Canadian Pharmacists Association.
• [13] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [14] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [15] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [18] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [19] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [22] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [23] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [24] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [25] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [26] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [27] Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
• [28] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [29] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [30] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [31] Multum Information Services, Inc. Expert Review Panel.
• [32] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [33] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [34] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [35] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [36] Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
• [37] Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
• [38] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [39] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [40] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
• [41] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [42] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [43] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [44] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [45] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [46] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [47] Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
• [48] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [49] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [50] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [51] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [52] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [53] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [54] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [55] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [56] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [57] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [58] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [59] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [60] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [61] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [62] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [63] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [64] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [65] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [66] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [67] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [68] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [69] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [70] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
• [71] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [72] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [73] Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
• [74] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [75] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [76] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [77] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [78] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [79] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [80] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [81] Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
• [82] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [83] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.